GeneDx to Present 18 Abstracts at ACMG 2026

Showcasing the Scale of GeneDx Infinity™ and Advancements in Rare Disease Diagnosis

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

GeneDx, a leader in rare disease diagnosis and genomic data, announced that it will present 18 abstracts at the upcoming American College of Medical Genetics and Genomics (ACMG) 2026 annual meeting. The presentations will highlight the scale and capabilities of GeneDx Infinity™, the company's advanced genomic testing platform, as well as advancements in rare disease diagnosis.

Why it matters

GeneDx's presentations at ACMG 2026 will showcase the company's position as a leader in rare disease diagnosis and its commitment to leveraging genomic data to improve health outcomes. The abstracts will provide insights into the latest developments in the field of rare disease genetics and the potential of advanced genomic testing to transform patient care.

The details

The 18 abstracts that GeneDx will present at ACMG 2026 will cover a range of topics, including the performance and scalability of the GeneDx Infinity™ platform, new gene discoveries and their clinical implications, and the use of genomic data to guide personalized treatment approaches for rare diseases.

  • GeneDx will present the 18 abstracts at the ACMG 2026 annual meeting, which is scheduled to take place in March 2026.

The players

GeneDx

A leader in rare disease diagnosis and improving health through the power of genomic data.

Got photos? Submit your photos here. ›

The takeaway

GeneDx's presentations at ACMG 2026 will showcase the company's commitment to advancing the field of rare disease diagnosis and its ability to leverage cutting-edge genomic technologies to improve patient outcomes. The abstracts will provide valuable insights into the latest developments in the field and the potential of genomic data to transform healthcare.